Абстракт

Objectives: To critically evaluate the current clinical evidence for PDRN in aesthetic dermatology, focusing on efficacy, safety, regulatory standing, and long-term risk–benefit balance. This review aims to determine whether its widespread use is scientifically justified, to highlight gaps between marketing claims and peer-reviewed data, and to identify research priorities, particularly in the context of potential immune-mediated adverse effects and the absence of standardized protocols. Introduction: Polydeoxyribonucleotide (PDRN), commonly sourced from salmon DNA, has gained astonishing popularity in aesthetic medicine under the "skin boosters", “skin-rejuvenation” category and is being promoted for enhancing skin rejuvenation, hydration, elasticity, and collagen synthesis. PDRN-based injectables are widely used worldwide. Despite its rapid commercial adoption, its scientific foundation remains weak, with limited high-quality trials and inconsistent methodology. Regulatory status varies, with no FDA approval for aesthetic indications. Concerns also persist regarding long-term safety. Materials / method: A systematic review of peer-reviewed literature was conducted, screening over 350 publications and 16 clinical trials related to PDRN for skin rejuvenation and wrinkle reduction. Eligible studies were classified according to Oxford Centre for Evidence-Based Medicine levels. Data extraction included study design, sample size, follow-up duration, objective measurement tools (e.g., Cutometer®, Corneometer®, 3D skin imaging, high-frequency ultrasound), and safety outcomes. Regulatory documents and manufacturer claims were reviewed for cross-validation against published evidence. Results: While a few randomized controlled trials (RCTs) suggest potential for PDRN in improving elasticity and texture, most studies fall into lower evidence categories (Levels IV–V). Sample sizes are small, methodologies are heterogeneous, and long-term data are lacking. No FDA-approved PDRN injectable exists for aesthetic use, and many products are used off-label. Surveys reveal widespread physician enthusiasm, but limited reliance on objective outcome measurements. Furthermore, studies often lack detailed molecular characterization and standardization in dosage or administration techniques. Conclusion: Salmon DNA-based skin boosters are widely used but remain poorly proven by robust scientific standards. The difference between claimed clinical efficacy and limited high-level evidence requires caution. Until FDA approves them and large, multicenter RCTs confirm their long-term safety and efficacy, PDRN should not be positioned as a gold-standard regenerative solution in aesthetic medicine. This presentation aims to bring up facts and promote evidence-based adoption of novel injectables instead. Conflict of interest: The author declares no conflict of interest related to this presentation.